Biomarker & Intervention Discovery
Kidney Stones (Nephrolithiasis)
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
Spontaneous remissionSpontaneous passage without intervention: 70-80% of stones <4 mm; 40-50% of stones 4-6mm; <25% of stones >6mm…
Best-intervention remissionAlpha-1 blockers (tamsulosin, 0.4mg): facilitate passage 30-45% faster for distal ureteral stones; ESWL: 75-80%…
Gap sizeModerate — metabolic evaluation and dietary prevention are highly effective but chronically underperformed after first…
Primary barrierpractice
Full remission profile →
Remission & chronicity
Spontaneous remission
Spontaneous passage without intervention: 70-80% of stones <4 mm; 40-50% of stones 4-6mm; <25% of stones >6mm; recurrence in 50% within 10 years without metabolic assessment and prevention
Best-intervention remission
Alpha-1 blockers (tamsulosin, 0.4mg): facilitate passage 30-45% faster for distal ureteral stones; ESWL: 75-80% stone-free for <2cm renal stones; PCNL: 90%+ stone-free for >2cm stones; dietary and metabolic prevention: 50% recurrence reduction with hydration + diet (STOP-JNKi-like approach)
Gap size
Moderate — metabolic evaluation and dietary prevention are highly effective but chronically underperformed after first stone
Only 10-20% of first-time kidney stone patients receive a 24-hour urine metabolic evaluation that would guide specific dietary and pharmacological prevention; high fluid intake (>2.5L/day) is evidence-based and free but rarely systematically emphasised; recurrence is highly preventable with appropriate dietary modification
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Kidney Stones (Nephrolithiasis)” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."